Healthcare / BiotechnologyNasdaqGM
$13.66
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-130.3M · quality 40.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-75.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+2.1%
FCF CAGR
—
FCF margin
-775.8%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $31.4M · net income $-232.0M · FCF $-243.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $31.4M | $31.4M | $43.3M | $46.0M | $41.4M | $36.9M | $34.4M | $20.4M | $4.6M | $7.5M | $1.6M | $26.6M | $3.5M | $2.1M | $3.5M | $5.0M | $23.1M |
| Net Income | $-232.0M | $-232.0M | $-130.9M | $-70.8M | $-102.3M | $-58.4M | $-45.4M | $-56.8M | $-86.1M | $-18.5M | $-21.5M | $6.3M | $-13.4M | $-11.9M | $-24.8M | $-8.6M | $8.8M |
| EBITDA | $-241.1M | $-241.1M | $-144.3M | $-74.6M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -3.17 | -3.17 | -2.32 | -1.82 | -2.74 | -2.03 | — | — | — | -0.52 | -0.68 | 0.21 | -0.49 | -0.52 | -1.19 | -0.44 | 0.46 |
| Operating Margin | -776.0% | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% | -108.3% | -235.0% | -853.6% | -246.4% | -1344.1% | 24.2% | -388.4% | -561.4% | -715.0% | -201.5% | 39.4% |
| Net Margin | -739.4% | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | -131.8% | -278.9% | -1884.2% | -245.2% | -1330.1% | 23.9% | -384.5% | -555.3% | -704.3% | -173.8% | 38.0% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | — | — | — | — | 0.30 | 0.20 | 2.05 | 5.67 | 0.47 | 0.00 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-243.4M | $-243.4M | $-130.3M | $-1.6M | $-67.2M | $-50.3M | $-14.8M | $-56.9M | — | $-20.6M | $-16.4M | — | — | $-8.8M | $-9.4M | $-3.3M | $9.9M |
| Returns | |||||||||||||||||
| ROE | -75.8% | -75.8% | -38.9% | -26.6% | -106.1% | -31.7% | -244.8% | -681.8% | -228.9% | -138.6% | -103.2% | 27.2% | -89.5% | -154.5% | -182.1% | -23.0% | 26.5% |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | -27.5% | -27.5% | -6.0% | 11.1% | 12.1% | 7.3% | 69.1% | 345.5% | -39.4% | 365.4% | -93.9% | 664.9% | 62.1% | -39.2% | -29.0% | -78.5% | — |
| EPS Growth | -36.6% | -36.6% | -27.5% | 33.6% | -35.0% | — | — | — | — | 23.5% | -423.8% | 142.9% | 5.8% | 56.3% | -170.5% | -195.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.